Triptorelin Extended-Release Suspension (Triptodur)

Triptodur (triptorelin ER) is covered only for the FDA‑approved treatment of central precocious puberty in pediatric patients aged ≥2 years (approval limited to females ≤11 years and males ≤12 years); off‑label uses are not covered. Approval (12 months) requires documented CPP by GnRH stimulation test or basal LH, and for initial authorization CNS abnormalities must be ruled out, bone age ≥1 year advanced, and onset of secondary sexual characteristics before age 8 (females) or 9 (males); reauthorization requires documented maintenance of LH suppression to prepubertal levels.

"Triptodur is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP)."

Sign up to see full coverage criteria, indications, and limitations.